1. Home
  2. HCWB vs GLMD Comparison

HCWB vs GLMD Comparison

Compare HCWB & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HCW Biologics Inc.

HCWB

HCW Biologics Inc.

HOLD

Current Price

$0.53

Market Cap

3.7M

Sector

Health Care

ML Signal

HOLD

Logo Galmed Pharmaceuticals Ltd.

GLMD

Galmed Pharmaceuticals Ltd.

HOLD

Current Price

$0.62

Market Cap

4.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HCWB
GLMD
Founded
2018
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7M
4.4M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
HCWB
GLMD
Price
$0.53
$0.62
Analyst Decision
Strong Buy
Hold
Analyst Count
1
1
Target Price
$35.00
N/A
AVG Volume (30 Days)
79.9K
72.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,099,750.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.50
52 Week High
$17.80
$3.50

Technical Indicators

Market Signals
Indicator
HCWB
GLMD
Relative Strength Index (RSI) 23.06 43.86
Support Level N/A N/A
Resistance Level $1.35 $0.87
Average True Range (ATR) 0.10 0.05
MACD -0.01 0.01
Stochastic Oscillator 5.35 59.85

Price Performance

Historical Comparison
HCWB
GLMD

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

About GLMD Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.

Share on Social Networks: